This article is more than 5 years old. Information may no longer be current.

Visual cycle modulator fails to meet primary endpoint of reducing GA growth rate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Acucela announced that the novel investigational visual cycle modulator emixustat hydrochloride failed to reduce geographic atrophy lesion growth rate in the SEATTLE study, according to a company press release.

There was no significant difference in geographic atrophy (GA) lesion growth rate, the primary endpoint of the phase 2b/3 clinical trial, between placebo and any of the three emixustat treatment groups over 2 years, according to the release.

In the study, 508 patients with GA secondary to age-related macular degeneration, received either 10 mg, 5 mg or 2.5 mg emixustat or placebo; growth rates were 1.84 mm², 1.83 mm², 1.69 mm² and 1.69 mm² per year, respectively.

“We are carefully reviewing the data in geographic atrophy before we decide on our next steps with emixustat in this indication,” Ryo Kubota, MD, PhD, chairman, president and CEO of Acucela, said in the release.

Acucela has launched a pilot study to explore the use of emixustat in treatment of proliferative diabetic retinopathy, according to the release.